Basic disclosure policy

Fuso Pharmaceutical Industries, Ltd. (hereafter “the Company”) discloses information to shareholders and investors, and other stakeholders in accordance with the statutory disclosure system based on the Financial Instruments and Exchange Act and the Timely Disclosure Rules established by the Tokyo Stock Exchange.
In addition, even for information that is not subject to statutory disclosure or Timely Disclosure Rules, the Company will disclose information that is deemed necessary for the investment decisions of shareholders and investors in a fair and prompt manner.

Disclosure methods

Information that falls under the Timely Disclosure Rules will be disclosed via the Timely Disclosure Network (TDnet) provided by the Tokyo Stock Exchange. Information published via TDnet and other channels will also be posted promptly on the Company’s website. Other information will also be disclosed through appropriate methods based on the nature of the information.

Quiet Period

The Company designates the period from the day after the closing date of each quarter until the date of the financial results announcement as a “Quiet Period.” During this period, the Company will refrain from making comments or answering questions regarding financial results. However, if a significant revision to the earnings forecast is expected, the Company will, in principle, disclose such information in accordance with the Timely Disclosure Rules.

Forward-Looking Statements

Information disclosed by the Company regarding future forecasts, such as earnings forecasts and research and development, is based on judgments made using information available at the time of disclosure. Please note that such information contains certain risks and uncertainties, and actual results may differ from the disclosed content.